Pfizer’s (PFE), OPKO’s BLA for Somatrogon Gets CRL From FDA

Posted byZacks Equity Research Leave a comment on Pfizer’s (PFE), OPKO’s BLA for Somatrogon Gets CRL From FDA

The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health’s biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.

Leave a comment

Your email address will not be published. Required fields are marked *